title: Morphological changes of bladder mucosa in patients who underwent instillation with combined sodium hyaluronic acid-chondroitin sulphate (Ialuril®).
abstract: OBJECTIVE
  To investigate what changes are endoscopically evident after glycosaminoglycans (GAGs) therapy by hyaluronic acid (HA) and chondroitin sulphate (CS) (Ialuril®) in female patients affected by bladder pain syndrome(BPS)/ interstitial cystitis (IC) or recurrent urinary tract infections (rUTIs).
  
  
  METHODS
  21 female patients over 18 years affected by rUTIs or BPS/IC received intravesical instillation of HA and CS (4 weekly instillations followed by 2 instillations every 2 weeks and 2 instillation monthly). Post-treatment evaluation included cystoscopy and patient assessment of improvement in symptoms and satisfaction on a visual analogue scale (VAS) from 0 to 10.
  
  
  RESULTS
  The post-treatment endoscopy showed a positive effect on bladder mucosa morphology. In 2 cases, treatment did not change endoscopic findings and clinical symptoms. In the other patients, when macroscopic features of the bladder mucosa normalized, the clinical picture improved.
  
  
  CONCLUSIONS
  GAGs therapy by HA and CS (Ialuril) improves the morphology of bladder mucosa in patients with rUTI or BPS/IC.
authors.affiliation: Department of Medical-Surgical Specialties and Public Health, Urology and Andrology Section, University of Perugia, Italy. ecostant@unipg.it
authors.forename: E
authors.initials: E
authors.lastname: Costantini
authors.forename: M
authors.initials: M
authors.lastname: Lazzeri
authors.forename: D
authors.initials: D
authors.lastname: Pistolesi
authors.forename: M
authors.initials: M
authors.lastname: Del Zingaro
authors.forename: E
authors.initials: E
authors.lastname: Frumenzio
authors.forename: A
authors.initials: A
authors.lastname: Boni
authors.forename: A
authors.initials: A
authors.lastname: Pietropaolo
authors.forename: E
authors.initials: E
authors.lastname: Fragalà
authors.forename: M
authors.initials: M
authors.lastname: Porena
mesh_terms: D000328:Adult; D000368:Aged; D002809:Chondroitin Sulfates / Q000008:administration & dosage* / Q000627:therapeutic use; D003556:Cystitis / Q000188:drug therapy; D018856:Cystitis, Interstitial / Q000188:drug therapy*; D003558:Cystoscopy; D004338:Drug Combinations; D004724:Endoscopy / Q000379:methods; D005260:Female; D006025:Glycosaminoglycans / Q000627:therapeutic use; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009092:Mucous Membrane / Q000473:pathology*; D001743:Urinary Bladder / Q000473:pathology*; D001745:Urinary Bladder Diseases / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy*; D019459:Urothelium / Q000378:metabolism / Q000473:pathology
chemical_list: D004338:Drug Combinations; D006025:Glycosaminoglycans; C501944:chondroitin sulfate, sodium hyaluronate drug combination; D006820:Hyaluronic Acid; D002809:Chondroitin Sulfates